AstraZeneca’s $1bn hypoparathyroidism drug gains success at Phase III

AstraZeneca’s investigational drug, eneboparatide, has met the primary endpoint in the Phase III Calypso trial for chronic hypoparathyroidism, a condition traditionally managed with calcium and vitamin D supplements. Currently, only one other therapy is approved for this rare disease.

The Calypso trial (NCT05778071) evaluated eneboparatide, a parathyroid hormone (PTH) receptor 1 agonist, and demonstrated its ability to normalize albumin-adjusted serum calcium levels while eliminating the need for active vitamin D and oral calcium therapy. Key secondary endpoints included improved 24-hour urinary calcium levels in patients with hypercalciuria and better patient-reported outcomes.

AstraZeneca acquired eneboparatide through its purchase of Amolyt Pharma in July 2024. These promising results position eneboparatide as a potential new treatment option, offering a more targeted and effective approach for patients with chronic hypoparathyroidism.

18-03-2025

• Pharma GMP
• Food GMP
• Clinical Research
• Medical Device
• Environmental Health and Safety
• Healthcare
• Nutrition